Vision, Integrity, Expertise
Soligenix, Inc. Soligenix, Inc. is a clinical stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as oral mucositis, pediatric Crohn's disease, acute radiation enteritis, and Graft-versus-Host disease (GVHD), and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.
Friday, February 14, 2014Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
Wednesday, February 05, 2014Soligenix to Present at the 16th Annual BIO CEO & Investor Conference in New York City
Thursday, January 16, 2014Soligenix Receives $750,000 in Non-Dilutive Financing from New Jersey’s Technology Business Tax Certificate Transfer Program
Partnering with Us
Soligenix is interested in identifying new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of HSC transplant, supportive cancer care, gastrointestinal and biodefense.